Meta AnalysisID 4021
经治HIV血清阳性患者中蛋白酶抑制剂暴露与糖尿病、妊娠期糖尿病及糖尿病前期风险：一项系统评价与Meta分析
CRD42020155399
What is the association between use of protease inhibitor and risk of diabetes, gestational diabetes and pre-diabetes among HIV sero-positive patients
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4021
- Evidence Id
- 12579
- Core Evidence Id
- 12579
- Source Meta Analysis Id
- 3979
- Herb2 Meta Analysis Id
- HBMA003979
- Crd Id
- CRD42020155399
- Title
- Protease Inhibitor Exposure and Risk of Diabetes Mellitus, Gestational Diabetes and Pre-diabetes Among Treated HIV Seropositive Patients: A Systematic Review and Meta-Analysis
- Review Question
- What is the association between use of protease inhibitor and risk of diabetes, gestational diabetes and pre-diabetes among HIV sero-positive patients
- Study Type Included
- case-control and cohort studies
- Condition Being Studied
- Diabetes: A heterogeneous group of disorders characterized by hyperglycemia and glucose intolerance; Gestational diabetes: Diabetes mellitus induced by pregnancy but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to insulin resistance, glucose intolerance and hyperglycemia.
- Participant
- Studies that with samples of HIV AIDS population
- Animal
- Human Disease Modelled
- Intervention
- Anti-retroviral medication belonging to the protease inhibitor class
- Comparator Control
- Non-exposed control group or Those exposed to other class of anti-retroviral therapy
- Main Outcome
- Diabetes incidence among HIV/AIDS patients treated with Protease Inhibitors. Measured based on change in baseline oral glucose oral glucose tolerance test (OGTT), blood glucose level, fasting blood glucose tests and Glycated hemoglobin (A1C) Measures of effect Time to diabetes development; odds of developing diabetes and risk of developing diabetes
- Outcome Measure
- Additional Outcome
- Diabetes incidence among pregnant HIV/AIDS patients treated with Protease Inhibitor.Measured based on change in baseline oral glucose oral glucose tolerance test (OGTT), blood glucose level, fasting blood glucose tests and Glycated hemoglobin (A1C) Measures of effect Time to diabetes development; odds of developing diabetes and risk of developing diabetes
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Humans
- Contact
- Eric Chinaeke [email protected]
- Organisational Affiliation
- University of South Carolina
- Funding Source
- No funding from organizations
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-10-21
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-10-25
- Anticipated Completion Date
- 2019-11-30
- Title Cn
- 经治HIV血清阳性患者中蛋白酶抑制剂暴露与糖尿病、妊娠期糖尿病及糖尿病前期风险：一项系统评价与Meta分析
- Title En
- Protease Inhibitor Exposure and Risk of Diabetes Mellitus, Gestational Diabetes and Pre-diabetes Among Treated HIV Seropositive Patients: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete